BCHT(SH:688276)2023-04-17 16:00Financial Performance - The company's operating revenue for Q1 2023 was RMB 179,431,529.21, representing a year-on-year increase of 30.21%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 18,381,036.97, reflecting a growth of 6.15% compared to the same period last year[4] - The basic earnings per share for Q1 2023 were RMB 0.04, unchanged from the previous year[4] - The weighted average return on equity for Q1 2023 was 0.51%, a decrease of 0.05 percentage points compared to the previous year[4] - Total revenue for Q1 2023 reached ¥179,431,529.21, an increase of 30.2% compared to ¥137,800,487.71 in Q1 2022[16] - Net profit for Q1 2023 was ¥18,743,021.97, slightly up from ¥18,638,951.23 in Q1 2022, showing a marginal growth of 0.6%[16] - The net profit for Q1 2023 was CNY 18,381,036.97, an increase from CNY 17,316,309.23 in Q1 2022, representing a growth of approximately 6.2%[17] - The total comprehensive income for Q1 2023 was CNY 17,034,520.01, compared to CNY 16,030,710.69 in Q1 2022, indicating an increase of about 6.3%[17] - The net profit for Q1 2023 was CNY 27,700,652.65, slightly down from CNY 27,897,596.24 in Q1 2022, representing a decrease of 0.7%[24] Research and Development - Research and development expenses totaled RMB 40,993,593.68, which is an increase of 32.73% year-on-year, accounting for 22.85% of operating revenue[6] - R&D expenses in Q1 2023 amounted to ¥33,403,636.31, compared to ¥27,599,666.15 in Q1 2022, indicating a 21.1% increase[16] - Research and development expenses for Q1 2023 were CNY 33,403,636.31, up from CNY 27,599,666.15 in Q1 2022, reflecting a growth of 21.1%[23] Assets and Liabilities - The total assets at the end of Q1 2023 were RMB 4,216,091,144.74, a decrease of 1.57% from the end of the previous year[6] - Cash and cash equivalents decreased to ¥793,550,910.20 as of March 31, 2023, down from ¥866,543,101.94 at the end of 2022, a decline of 8.4%[12] - Accounts receivable decreased to ¥876,938,102.49 from ¥968,406,297.16, a reduction of 9.5%[12] - Inventory increased to ¥224,607,989.80 from ¥192,110,041.70, representing a growth of 16.9%[13] - Total assets as of March 31, 2023, were ¥4,216,091,144.74, a slight decrease from ¥4,283,551,750.23 at the end of 2022, down by 1.6%[14] - Total liabilities decreased to ¥629,153,586.92 from ¥724,015,550.19, a reduction of 13.1%[14] - The total assets as of Q1 2023 amounted to CNY 4,468,055,870.41, a decrease of 1.2% from CNY 4,524,486,571.41 in the previous year[22] - The total liabilities for Q1 2023 were CNY 612,482,582.03, down 13.2% from CNY 705,634,256.49 in Q1 2022[22] Cash Flow - The company reported a net cash flow from operating activities of RMB -4,585,538.96, which is not applicable for year-on-year comparison[4] - Cash inflow from operating activities in Q1 2023 was CNY 217,658,504.45, an increase of 23.0% compared to CNY 176,992,310.79 in Q1 2022[25] - The cash inflow from operating activities totaled CNY 217,664,822.46 in Q1 2023, compared to CNY 177,009,234.06 in Q1 2022, marking an increase of approximately 22.9%[18] - The cash outflow for operating activities was CNY 222,250,361.42 in Q1 2023, down from CNY 258,924,937.66 in Q1 2022, indicating a decrease of about 14.2%[18] - The company reported a decrease in cash paid to employees to CNY 50,291,436.66 in Q1 2023 from CNY 64,461,020.77 in Q1 2022, a reduction of approximately 22%[18] - The net cash flow from operating activities was -$16.89 million, an improvement from -$81.62 million in the previous period[27] - Total cash outflow from operating activities amounted to $234.55 million, down from $258.61 million year-over-year[27] Government Support and Future Plans - The company received government subsidies amounting to RMB 822,471.36 during the reporting period[7] - The company has received approval for the marketing authorization of its live attenuated varicella-zoster vaccine from the National Medical Products Administration[11] - The company is planning to issue Global Depository Receipts (GDRs) and list them on the Swiss Stock Exchange, backed by newly issued A-shares[11] Other Financial Metrics - The company’s total current assets were CNY 2,246,644,542.89 in Q1 2023, a slight decrease from CNY 2,338,251,177.59 in Q4 2022[20] - The company's total equity as of Q1 2023 was CNY 3,855,573,288.38, an increase of 1.0% from CNY 3,818,852,314.92 in Q1 2022[22] - The company reported a decrease in other comprehensive income, with a net amount of CNY -1,346,516.96 in Q1 2023 compared to CNY -1,285,598.54 in Q1 2022[24] - The company's cash paid for purchasing goods and services in Q1 2023 was CNY 27,694,777.69, significantly lower than CNY 64,930,206.82 in Q1 2022, indicating a decrease of 57.3%[25] - The total non-current assets as of Q1 2023 were CNY 2,221,411,327.52, a slight increase from CNY 2,186,235,393.82 in the previous year[22] - The impact of exchange rate changes on cash and cash equivalents was -$61,639.03, slightly better than -$70,944.11 previously[27] - The company did not apply new accounting standards for the current reporting period[28]